Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1920 in Primary Membranous Nephropathy
NCT07157787Phase 2Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
A Phase 2 trial of ALXN-1920 in primary membranous nephropathy (PMN), sponsored by Alexion Pharmaceuticals. Started Sep 2025; status: recruiting.
02
Drugs
ALXN-1920
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT07157787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07157787.